The Chinese capital Beijing is intending to create what it calls a"Medicines Valley," a center for the pharmaceutical industry, according to the Xinhua news agency. This will be based on an existing pharmaceutical industry center in the Beijing Economic and Technological Development Zone.
Two branches of Tongrentang, China's largest producer of traditional Chinese medicines, are already located in the center, in which corporate investment has so far reached $410 million. The center recorded an output value of 1.5 billion renminbi ($181 million) last year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze